# Safety and Immunogenicity of a Recombinant Poliomyelitis Vaccine (rPV) in Comparison With IPOL Vaccine in Healthy Adults

> **NCT07688369** · PHASE1 · RECRUITING · sponsor: **Serum Institute of India Pvt. Ltd.** · enrollment: 36 (estimated)

## Conditions studied

- Polio Immunity

## Interventions

- **BIOLOGICAL:** Recombinant Poliomyelitis Vaccine (rPV)
- **BIOLOGICAL:** Inactivated Poliomyelitis Vaccine (IPOL)

## Key facts

- **NCT ID:** NCT07688369
- **Lead sponsor:** Serum Institute of India Pvt. Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-09-11
- **Primary completion:** 2026-11
- **Final completion:** 2027-03
- **Target enrollment:** 36 (ESTIMATED)
- **Last updated:** 2026-09-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07688369

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07688369, "Safety and Immunogenicity of a Recombinant Poliomyelitis Vaccine (rPV) in Comparison With IPOL Vaccine in Healthy Adults". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07688369. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*